世界の多形性膠芽腫治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2586 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、多形性膠芽腫治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ベバシズマブ（アバスチン）、カルムスチン（BiCNU）、テモゾロミド（テモダー・テモーダル・テムカッド））、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・多形性膠芽腫治療の市場動向 ・企業の競争状況、市場シェア ・多形性膠芽腫治療の種類別市場規模（ベバシズマブ（アバスチン）、カルムスチン（BiCNU）、テモゾロミド（テモダー・テモーダル・テムカッド）） ・多形性膠芽腫治療の用途別市場規模（病院、クリニック、その他） ・多形性膠芽腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・多形性膠芽腫治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・多形性膠芽腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・多形性膠芽腫治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・多形性膠芽腫治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AbbVie, Inc、Activartis GmbH、Agenus Inc、Arog Pharmaceuticals, Inc、Bristol-Myers Squibb Company、Cavion LLC、Celldex Therapeutics Inc、Cortice Biosciences、Exelixis Inc、F. Hoffmann-La Roche Ltd.） ・結論

Market Analysis and Insights: Global Glioblastoma Multiforme Treatment Market
The global Glioblastoma Multiforme Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Glioblastoma Multiforme Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Glioblastoma Multiforme Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Glioblastoma Multiforme Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Glioblastoma Multiforme Treatment market.

Global Glioblastoma Multiforme Treatment Scope and Market Size
Glioblastoma Multiforme Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glioblastoma Multiforme Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Bevacizumab (Avastin)
Carmustine (BiCNU)
Temozolomide (Temodar and Temodal and Temcad)

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie, Inc
Activartis GmbH
Agenus Inc
Arog Pharmaceuticals, Inc
Bristol-Myers Squibb Company
Cavion LLC
Celldex Therapeutics Inc
Cortice Biosciences
Exelixis Inc

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Bevacizumab (Avastin)
1.2.3 Carmustine (BiCNU)
1.2.4 Temozolomide (Temodar and Temodal and Temcad)
1.3 Market by Application
1.3.1 Global Glioblastoma Multiforme Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Glioblastoma Multiforme Treatment Market Perspective (2016-2027)
2.2 Glioblastoma Multiforme Treatment Growth Trends by Regions
2.2.1 Glioblastoma Multiforme Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Glioblastoma Multiforme Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Glioblastoma Multiforme Treatment Industry Dynamic
2.3.1 Glioblastoma Multiforme Treatment Market Trends
2.3.2 Glioblastoma Multiforme Treatment Market Drivers
2.3.3 Glioblastoma Multiforme Treatment Market Challenges
2.3.4 Glioblastoma Multiforme Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Glioblastoma Multiforme Treatment Players by Revenue
3.1.1 Global Top Glioblastoma Multiforme Treatment Players by Revenue (2016-2021)
3.1.2 Global Glioblastoma Multiforme Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Glioblastoma Multiforme Treatment Revenue
3.4 Global Glioblastoma Multiforme Treatment Market Concentration Ratio
3.4.1 Global Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Treatment Revenue in 2020
3.5 Glioblastoma Multiforme Treatment Key Players Head office and Area Served
3.6 Key Players Glioblastoma Multiforme Treatment Product Solution and Service
3.7 Date of Enter into Glioblastoma Multiforme Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Glioblastoma Multiforme Treatment Breakdown Data by Type
4.1 Global Glioblastoma Multiforme Treatment Historic Market Size by Type (2016-2021)
4.2 Global Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2022-2027)

5 Glioblastoma Multiforme Treatment Breakdown Data by Application
5.1 Global Glioblastoma Multiforme Treatment Historic Market Size by Application (2016-2021)
5.2 Global Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Glioblastoma Multiforme Treatment Market Size (2016-2027)
6.2 North America Glioblastoma Multiforme Treatment Market Size by Type
6.2.1 North America Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
6.2.2 North America Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
6.2.3 North America Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
6.3 North America Glioblastoma Multiforme Treatment Market Size by Application
6.3.1 North America Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
6.3.2 North America Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
6.3.3 North America Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
6.4 North America Glioblastoma Multiforme Treatment Market Size by Country
6.4.1 North America Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
6.4.2 North America Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Glioblastoma Multiforme Treatment Market Size (2016-2027)
7.2 Europe Glioblastoma Multiforme Treatment Market Size by Type
7.2.1 Europe Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
7.2.2 Europe Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
7.2.3 Europe Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
7.3 Europe Glioblastoma Multiforme Treatment Market Size by Application
7.3.1 Europe Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
7.3.2 Europe Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
7.3.3 Europe Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
7.4 Europe Glioblastoma Multiforme Treatment Market Size by Country
7.4.1 Europe Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
7.4.2 Europe Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Glioblastoma Multiforme Treatment Market Size (2016-2027)
8.2 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Type
8.2.1 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Application
8.3.1 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region
8.4.1 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Glioblastoma Multiforme Treatment Market Size (2016-2027)
9.2 Latin America Glioblastoma Multiforme Treatment Market Size by Type
9.2.1 Latin America Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
9.3 Latin America Glioblastoma Multiforme Treatment Market Size by Application
9.3.1 Latin America Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
9.4 Latin America Glioblastoma Multiforme Treatment Market Size by Country
9.4.1 Latin America Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Glioblastoma Multiforme Treatment Market Size (2016-2027)
10.2 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Type
10.2.1 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Application
10.3.1 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country
10.4.1 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie, Inc
11.1.1 AbbVie, Inc Company Details
11.1.2 AbbVie, Inc Business Overview
11.1.3 AbbVie, Inc Glioblastoma Multiforme Treatment Introduction
11.1.4 AbbVie, Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.1.5 AbbVie, Inc Recent Development
11.2 Activartis GmbH
11.2.1 Activartis GmbH Company Details
11.2.2 Activartis GmbH Business Overview
11.2.3 Activartis GmbH Glioblastoma Multiforme Treatment Introduction
11.2.4 Activartis GmbH Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.2.5 Activartis GmbH Recent Development
11.3 Agenus Inc
11.3.1 Agenus Inc Company Details
11.3.2 Agenus Inc Business Overview
11.3.3 Agenus Inc Glioblastoma Multiforme Treatment Introduction
11.3.4 Agenus Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.3.5 Agenus Inc Recent Development
11.4 Arog Pharmaceuticals, Inc
11.4.1 Arog Pharmaceuticals, Inc Company Details
11.4.2 Arog Pharmaceuticals, Inc Business Overview
11.4.3 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Introduction
11.4.4 Arog Pharmaceuticals, Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.4.5 Arog Pharmaceuticals, Inc Recent Development
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Details
11.5.2 Bristol-Myers Squibb Company Business Overview
11.5.3 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Introduction
11.5.4 Bristol-Myers Squibb Company Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.5.5 Bristol-Myers Squibb Company Recent Development
11.6 Cavion LLC
11.6.1 Cavion LLC Company Details
11.6.2 Cavion LLC Business Overview
11.6.3 Cavion LLC Glioblastoma Multiforme Treatment Introduction
11.6.4 Cavion LLC Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.6.5 Cavion LLC Recent Development
11.7 Celldex Therapeutics Inc
11.7.1 Celldex Therapeutics Inc Company Details
11.7.2 Celldex Therapeutics Inc Business Overview
11.7.3 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Introduction
11.7.4 Celldex Therapeutics Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.7.5 Celldex Therapeutics Inc Recent Development
11.8 Cortice Biosciences
11.8.1 Cortice Biosciences Company Details
11.8.2 Cortice Biosciences Business Overview
11.8.3 Cortice Biosciences Glioblastoma Multiforme Treatment Introduction
11.8.4 Cortice Biosciences Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.8.5 Cortice Biosciences Recent Development
11.9 Exelixis Inc
11.9.1 Exelixis Inc Company Details
11.9.2 Exelixis Inc Business Overview
11.9.3 Exelixis Inc Glioblastoma Multiforme Treatment Introduction
11.9.4 Exelixis Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.9.5 Exelixis Inc Recent Development
11.10 F. Hoffmann-La Roche Ltd.
11.10.1 F. Hoffmann-La Roche Ltd. Company Details
11.10.2 F. Hoffmann-La Roche Ltd. Business Overview
11.10.3 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Introduction
11.10.4 F. Hoffmann-La Roche Ltd. Revenue in Glioblastoma Multiforme Treatment Business (2016-2021)
11.10.5 F. Hoffmann-La Roche Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Bevacizumab (Avastin)
Table 3. Key Players of Carmustine (BiCNU)
Table 4. Key Players of Temozolomide (Temodar and Temodal and Temcad)
Table 5. Global Glioblastoma Multiforme Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Glioblastoma Multiforme Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Glioblastoma Multiforme Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Glioblastoma Multiforme Treatment Market Share by Regions (2016-2021)
Table 9. Global Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Glioblastoma Multiforme Treatment Market Share by Regions (2022-2027)
Table 11. Glioblastoma Multiforme Treatment Market Trends
Table 12. Glioblastoma Multiforme Treatment Market Drivers
Table 13. Glioblastoma Multiforme Treatment Market Challenges
Table 14. Glioblastoma Multiforme Treatment Market Restraints
Table 15. Global Glioblastoma Multiforme Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Glioblastoma Multiforme Treatment Market Share by Players (2016-2021)
Table 17. Global Top Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme Treatment as of 2020)
Table 18. Ranking of Global Top Glioblastoma Multiforme Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Glioblastoma Multiforme Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Glioblastoma Multiforme Treatment Product Solution and Service
Table 22. Date of Enter into Glioblastoma Multiforme Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Glioblastoma Multiforme Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Glioblastoma Multiforme Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Glioblastoma Multiforme Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Glioblastoma Multiforme Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Glioblastoma Multiforme Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. AbbVie, Inc Company Details
Table 63. AbbVie, Inc Business Overview
Table 64. AbbVie, Inc Glioblastoma Multiforme Treatment Product
Table 65. AbbVie, Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 66. AbbVie, Inc Recent Development
Table 67. Activartis GmbH Company Details
Table 68. Activartis GmbH Business Overview
Table 69. Activartis GmbH Glioblastoma Multiforme Treatment Product
Table 70. Activartis GmbH Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 71. Activartis GmbH Recent Development
Table 72. Agenus Inc Company Details
Table 73. Agenus Inc Business Overview
Table 74. Agenus Inc Glioblastoma Multiforme Treatment Product
Table 75. Agenus Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 76. Agenus Inc Recent Development
Table 77. Arog Pharmaceuticals, Inc Company Details
Table 78. Arog Pharmaceuticals, Inc Business Overview
Table 79. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Product
Table 80. Arog Pharmaceuticals, Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 81. Arog Pharmaceuticals, Inc Recent Development
Table 82. Bristol-Myers Squibb Company Company Details
Table 83. Bristol-Myers Squibb Company Business Overview
Table 84. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Product
Table 85. Bristol-Myers Squibb Company Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 86. Bristol-Myers Squibb Company Recent Development
Table 87. Cavion LLC Company Details
Table 88. Cavion LLC Business Overview
Table 89. Cavion LLC Glioblastoma Multiforme Treatment Product
Table 90. Cavion LLC Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 91. Cavion LLC Recent Development
Table 92. Celldex Therapeutics Inc Company Details
Table 93. Celldex Therapeutics Inc Business Overview
Table 94. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Product
Table 95. Celldex Therapeutics Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 96. Celldex Therapeutics Inc Recent Development
Table 97. Cortice Biosciences Company Details
Table 98. Cortice Biosciences Business Overview
Table 99. Cortice Biosciences Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 100. Cortice Biosciences Recent Development
Table 101. Exelixis Inc Company Details
Table 102. Exelixis Inc Business Overview
Table 103. Exelixis Inc Glioblastoma Multiforme Treatment Product
Table 104. Exelixis Inc Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 105. Exelixis Inc Recent Development
Table 106. F. Hoffmann-La Roche Ltd. Company Details
Table 107. F. Hoffmann-La Roche Ltd. Business Overview
Table 108. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Product
Table 109. F. Hoffmann-La Roche Ltd. Revenue in Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 110. F. Hoffmann-La Roche Ltd. Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glioblastoma Multiforme Treatment Market Share by Type: 2020 VS 2027
Figure 2. Bevacizumab (Avastin) Features
Figure 3. Carmustine (BiCNU) Features
Figure 4. Temozolomide (Temodar and Temodal and Temcad) Features
Figure 5. Global Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Others Case Studies
Figure 9. Glioblastoma Multiforme Treatment Report Years Considered
Figure 10. Global Glioblastoma Multiforme Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Glioblastoma Multiforme Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Glioblastoma Multiforme Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Glioblastoma Multiforme Treatment Market Share by Regions (2022-2027)
Figure 14. Global Glioblastoma Multiforme Treatment Market Share by Players in 2020
Figure 15. Global Top Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme Treatment Revenue in 2020
Figure 17. Global Glioblastoma Multiforme Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Glioblastoma Multiforme Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 21. North America Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 22. North America Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 23. United States Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 27. Europe Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 28. Europe Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 29. Germany Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Glioblastoma Multiforme Treatment Market Share by Region (2016-2027)
Figure 39. China Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. AbbVie, Inc Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 59. Activartis GmbH Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 60. Agenus Inc Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 61. Arog Pharmaceuticals, Inc Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 63. Cavion LLC Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 64. Celldex Therapeutics Inc Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 65. Cortice Biosciences Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 66. Exelixis Inc Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 67. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---